Senescent cells: remove them or change their behavior?

Longevitytech.fund — supporting longevity research

We are proud of Longevity Tech Fund's support for SENISCA's research into RNA processing and cellular senescence. A June 2022 University of Exeter announcement named the fund among existing SENISCA investors participating in that financing round.[8]

What the evidence shows

• Shown: some senescence-related features can change in cultured human cells, and the response differs by cell type and intervention.[1] [2] [3]

• Not shown: that SENISCA's approach restores health in patients, that changing a cell's state is safer than removing it, or that either strategy provides general human rejuvenation.[1] [2] [3] [4] [5] [6] [7]

• What would change the assessment: a defined treatment that restores useful tissue function, retains appropriate control of cell growth, and improves patient outcomes in controlled trials with adequate safety follow-up.

The evidence described here is dated September 22, 2026. The foundational RNA-processing experiments used cells in laboratory culture. Human cells in a dish are distinct from a treatment tested in people.

A senescent cell is alive, but its behavior has changed

Senescence is a state associated with stress in which a cell persistently stops dividing and changes other activities. Some senescent cells release inflammatory or tissue-altering signals. Researchers call this mixture the senescence-associated secretory phenotype, or SASP. The term describes what the cell releases, not a single substance.[1] [2]

Senescent does not mean every old cell, and these cells are not simply asleep. Stopping division can help restrain damaged or potentially malignant cells. Removing that restraint therefore needs careful testing. The effect of senescence depends on the cell, the tissue and what caused it.[7]

Researchers are pursuing three overlapping strategies:

The word senomorphic is sometimes used for interventions that modify features of senescence without selectively killing cells. It covers different approaches; it does not describe one established treatment.[1] [2] [3]

These distinctions matter when interpreting images. Fewer cells staining positive for a senescence marker could mean that cells died, changed state, or stopped displaying that marker while retaining other problems. Cell survival and function need to be measured separately.

Why RNA splicing matters

A cell processes an RNA message before using it to make a protein. Alternative splicing lets the cell combine different sections of that message. Proteins called splicing factors help regulate those choices, rather like deciding which sections of an instruction manual to keep.[1] [4]

The Exeter research group linked age-associated changes in this machinery with senescence. In a 2017 experiment, researchers treated cultures from three human fibroblast strains with resveratrol-related compounds. Fibroblasts help maintain connective tissue; these strains came from skin and lung tissue and had already divided many times in culture. Key experiments assessed a 24-hour exposure against a vehicle control—the same carrier without the active compound.[1]

Treatment changed the amounts of RNA messages for splicing factors and several senescence-related features. Cells resumed division when growth conditions allowed it. Measurements of cell death argued against selective killing as the explanation. That is meaningful evidence that surviving cells can change state. The cultures contained mixed populations, however, so the study did not show that every senescent cell responded.[1]

The molecules and conditions also matter. This was a controlled laboratory exposure to resveratrol-related compounds, not a trial of red wine, an oral resveratrol supplement or a final SENISCA product in patients. The academic finding gives a reason to investigate a mechanism, not a way to reproduce the result at home.

The mixed results explain what “reversal” leaves out

In 2018, researchers used compounds that release hydrogen sulfide, including forms designed to reach mitochondria, the structures involved in cellular energy production. In cultured human endothelial cells, which line blood vessels, treatment reduced several senescence markers and implicated two splicing factors, HNRNPD and SRSF2. The main comparisons were made after 24 hours against a carrier-only control.[2]

Several other findings moved in a different direction:

• Overall cell division did not return, although a small subset showed more DNA replication.

• Telomere length—the length of protective chromosome ends—was not restored.

• The measured DNA-damage marker did not improve.

• IL-8, an inflammatory signal, increased.[2]

A later study tested trametinib in skin fibroblasts from people with three rare syndromes associated with premature aging. Compared with carrier-only treatment, senescence staining decreased in Hutchinson–Gilford progeria and Cockayne syndrome cells, but not in Werner syndrome cells. Cockayne cells also divided less despite the improved senescence marker.[3]

There was one donor-derived cell line for each syndrome. Repeating laboratory experiments improves confidence in a measurement; it does not turn one donor into a representative patient population. These rare conditions also cannot stand in for ordinary aging.[3]

Together, the studies show that “reversal” needs a specific object: which feature changed, in which cells, after which intervention? A real improvement in one feature can coexist with other unresolved damage.

What SENISCA is developing

SENISCA, a University of Exeter spinout, describes oligonucleotide approaches intended to reset splicing-factor levels. Oligonucleotides are short pieces of DNA or RNA that can be designed to influence RNA-related processes. Its public program describes work in idiopathic pulmonary fibrosis, a disease that scars the lungs, and in skin health.[4]

The company's March 18, 2024 financing announcement described preclinical development and preparation of data for investigational-drug work. It also described a rationale for treatments delivered locally to the target tissue. That dated development milestone is separate from a clinical-results report.[5]

The company descriptions do not provide a controlled patient result showing improved lung function or prevention of disability. A lung-disease treatment, a skincare collaboration and a treatment aimed at aging throughout the body pose different questions. An improvement in one setting cannot establish the others.[4] [5]

Delivery is a substantial part of the work: a candidate must reach the right tissue, change the intended RNA process and avoid unwanted effects elsewhere. Those properties must be demonstrated for the particular molecule and route of administration. The potential precision of RNA technology does not establish them automatically.

Could preserving a cell be safer?

Preserving a cell could help if it regains useful function. Allowing a damaged cell to grow without correcting the underlying problem could have a different effect. There is no direct treatment comparison here establishing that state change is safer than removal.

A cancer-model experiment illustrates why growth control matters. Researchers studied mouse lymphoma cells that had entered senescence after chemotherapy. Cells released from that arrest had a greater ability to start tumors than similarly chemotherapy-exposed cells that had not entered senescence; human cancer systems provided supporting observations. These were malignant cells in a specialized setting. The experiment did not test normal tissues treated with a SENISCA product and does not establish that its approach causes cancer.[7]

Cell-removal strategies have their own questions: which cells are killed, whether useful cells are spared, and whether the tissue works better afterward. Neither preserving nor removing cells is a sufficient safety argument on its own.

What the human senolytic comparison tells us

Senolytics have reached human trials, but their results cannot validate a different RNA-based candidate. In a randomized phase 2 trial, 60 postmenopausal women received intermittent dasatinib plus quercetin or were in a control group. The primary, or main planned, outcome was the change at 20 weeks in CTx, a blood marker of bone breakdown. There was no statistically significant difference between groups.[6]

P1NP, a secondary marker of bone formation, improved at weeks 2 and 4 but not at week 20. Exploratory subgroup findings offered ideas for later testing; they did not make the overall primary result positive. The trial measured bone markers, not fewer fractures.[6]

This result applies to that treatment, population, schedule and outcome. It does not establish that every senolytic fails or that changing cell state is the superior alternative.

How Healthy Longevity Clinic experts evaluate the evidence

For someone hoping to stay active or preserve organ function, the useful question is whether a treatment helps the tissue do its job. Fewer stained cells are an intermediate observation. HLC's interpretation separates four findings: the cells survived, selected markers changed, appropriate function returned, and a patient benefited. Each requires its own evidence.

The endothelial experiment makes the distinction concrete: several senescence markers fell while the DNA-damage measure did not improve and IL-8 rose. That is a reason to examine the whole response before calling it rejuvenation. In a conversation about lung health, for example, the decisive evidence would concern lung function and patient outcomes, not simply a splicing change in cultured cells.[2] [4]

A useful clinical discussion therefore starts with the person's actual problem and the specific proposed product. The existing findings support further research into senescence; they do not identify a clinically superior strategy for healthy aging. The assessment would change with controlled, candidate-specific patient results showing meaningful functional benefit, durability and acceptable safety, including appropriate growth control. Historical investment and laboratory plausibility answer different questions from those clinical tests.

Three questions to bring to a clinical conversation

1. What health problem would this particular treatment aim to improve, and has it been studied in people with that problem?

2. Did the study show better tissue or patient function, or only fewer cells carrying a laboratory marker?

3. How were unwanted cell growth, effects on other tissues and the durability of any benefit assessed?

Common questions

Does “human cells” mean a human trial?

No. The foundational splicing experiments studied human-derived cells in culture. They reveal possible mechanisms, but they do not measure how a treatment behaves throughout a person's body.[1] [2] [3]

Does the 2017 result support taking resveratrol?

It does not establish that an oral supplement recreates the experimental exposure or benefit. The study also used a different set of molecules from SENISCA's oligonucleotide program.[1] [4]

Do all senescent cells need to be removed?

The label alone does not decide that. Senescence can restrain damaged cells, while some senescent cells also produce harmful signals. The relevant question is whether changing or removing a defined population improves tissue function safely.[1] [2] [7]